Apexigen, Inc.
Records under this name other than the patents Apexigen, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 9 patents it holds.
Showing 1 to 6 of 6 · Back to Apexigen, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,986,692 | Anti-VEGF Monoclonal Antibody and Pharmaceutical Composition Comprising Said Antibody Formerly held In force · High confidence | In force | High confidence | |
| US 8,753,634 | Anti-IL-6 receptor antibodies and methods of use Lapsed on the fee record Ended Jun 17, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 17, 2026 | From the USPTO record |
| US 9,951,136 | Anti-IL-6 receptor antibodies and methods of use Lapsed on the fee record Ended Apr 24, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 24, 2026 | From the USPTO record |
| US 11,078,283 | Anti-PD-L1 antibodies and methods of use Lapsed on the fee record Ended Aug 3, 2025 · From the USPTO record | Lapsed on the fee record | Ended Aug 3, 2025 | From the USPTO record |
| US 9,441,042 | Anti-KDR antibodies and methods of use Lapsed on the fee record Ended Sep 13, 2024 · From the USPTO record | Lapsed on the fee record | Ended Sep 13, 2024 | From the USPTO record |
| US 9,085,621 | Anti-IL-1β antibodies Lapsed on the fee record Ended Jul 21, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jul 21, 2023 | From the USPTO record |